GlassScriptPhysician profile
Ben Z Cohen
NPI 1083608186
$5,460.37
in general payments reported to CMS, 2019-2025
25 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 79% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $268 · 2021: $290 · 2022: $363 · 2023: $1,923 · 2024: $1,056 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030 · Consulting Fee: $1,300 · Education: $35.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.48 |
| Consulting Fee | $1,300.00 |
| Education | $35.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $1,300.00 | 2023 | Forum, Forum Glaucoma Workplace, Humphrey Hfa |
| Janssen Biotech, INC. | $654.38 | 2024-2025 | Tremfya, Stelara |
| Alcon Vision LLC | $591.26 | 2020-2025 | Centurion, Clareon, Unity |
| Abbvie INC. | $356.20 | 2020-2025 | Vuity, Ozurdex, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $350.77 | 2023-2025 | Tecnis Iol, Tecnis Iol, Veritas Vision System |
| Alimera Sciences, INC. | $275.07 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $250.76 | 2019-2025 | Eylea Hd |
| Alphatec Spine, INC | $247.09 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.79 | 2025 | Entyvio |
| Rxsight INC | $195.98 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Novartis Pharmaceuticals Corporation | $175.19 | 2019-2020 | |
| Genentech, INC. | $150.00 | 2025 | Susvimo |
| Bausch & Lomb Americas INC. | $143.59 | 2022-2025 | Prolensa, Envista Aspire Iol, Envista Envy Iol |
| Apellis Pharmaceuticals, INC. | $115.32 | 2022-2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.39 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iridex Corporation | $78.03 | 2025 | |
| Allergan, INC. | $50.11 | 2019-2021 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $46.94 | 2024 | |
| Ucb, INC. | $42.06 | 2019-2020 | |
| Astellas Pharma US INC | $26.26 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $25.24 | 2025 | |
| Genentech USA, INC. | $24.27 | 2019 | |
| Glaukos Corporation | $20.67 | 2025 | Idosetr |
| Dutch Ophthalmic, USA | $18.00 | 2023 | Tissueblue, Eva, Combined Machine |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.